Document Detail

Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells.
MedLine Citation:
PMID:  19739078     Owner:  NLM     Status:  MEDLINE    
The development of multidrug resistance (MDR) is a major problem during cancer treatment. Drug efflux via ATP-binding cassette (ABC) transporters is the main mechanism responsible for resistance to chemotherapeutics. We have recently observed that statins enhance susceptibility to doxorubicin-induced apoptosis in human rhabdomyosarcoma cells, which is now also observed in human SH-SY5Y neuroblastoma cells. We have therefore investigated the ABC transporter activity to confirm a possible inhibition by statins in SH-SY5Y cells. Indeed, simvastatin directly inhibited dye transport at equimolar concentrations of the ABC transporter inhibitor, verapamil. Making use of the fluorescence behavior of doxorubicin the accumulation of anthracycline was monitored in real-time confocal microscopy. The intracellular doxorubicin accumulation was immediately enhanced by statins in SH-SY5Y cells and also in a MYCN-amplified neuroblastoma cell line STA-NB-10. The heavily glycosylated P-glycoprotein (ABCB1, P-gp) transporter appeared as a 180-and 140-kDa species. Atorvastatin and simvastatin reduced the 180-kDa form of P-gp, but not verapamil. Thereby the fully glycosylated species is shifted to the core glycosylated species (140 kDa), which was only seen at statin exposure times longer than 24 hr. The functional importance of glycosylation of the transporter was highlighted by exogenous application of N-glycosidase F, which was sufficient to enhance doxorubicin accumulation. Hence, these novel findings of statins' dual impact on P-gp have clinical implications. The enhanced intracellular accumulation of chemotherapeutics or other ABC transporter substrates in the presence of statins may represent a novel concept to overcome MDR in cancer therapy and improve drug safety.
Evelyn Sieczkowski; Claudia Lehner; Peter F Ambros; Martin Hohenegger
Related Documents :
20092888 - Trafficking microenvironmental phs of polycationic gene vectors in drug-sensitive and m...
19291828 - Antisense expression of pkcalpha improved sensitivity of sgc7901/vcr cells to doxorubicin.
19926538 - Effect of the anti-neoplastic drug doxorubicin on xpd-mutated dna repair-deficient huma...
20030928 - Combined effects of bortezomib and daunorubicin on multiple myeloma cell km3 in vitro.
2161348 - Mg2+ mediates the cell-substratum interaction of arg-gly-asp-dependent hela cell collag...
21389048 - Direct in vivo cellular reprogramming involves transition through discrete, non-pluripo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  126     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-03-01     Completed Date:  2010-03-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2025-35     Citation Subset:  IM    
Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
ATP-Binding Cassette Transporters / antagonists & inhibitors
Cell Line, Tumor
Doxorubicin / pharmacokinetics,  pharmacology
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
Neuroblastoma / drug therapy*,  metabolism,  pathology
P-Glycoprotein / antagonists & inhibitors*,  metabolism
Simvastatin / pharmacology
Reg. No./Substance:
0/ATP-Binding Cassette Transporters; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/P-Glycoprotein; 23214-92-8/Doxorubicin; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Next Document:  The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II st...